TAK, US8740602052

Takeda presents TAK-881 trial data for Takeda stock

Published on 10/20/2026 at 09:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Takeda's trial met its primary endpoint on October 14, 2026. Takeda stock costs EUR 17.75 on October 20, 2026 while trial volume fell 50.00 percent.

Trial data and reporting date

Takeda's TAK-881 study met its primary endpoint on October 14, 2026, with a 50.00 percent volume reduction.
Infusion time fell by 56.20 minutes, or 42.60 percent, at one infusion site.
Takeda stock was trading at EUR 17.75 at 8:59 a.m. CEST at Lang & Schwarz on October 20, 2026.
Takeda will release fiscal 2026 second-quarter results on October 29, 2026.

TAK, US8740602052, Illustration mit AI erstellt.

Takeda Pharmaceutical Company Limited (ISIN US8740602052) was trading at EUR 17.75 at Lang & Schwarz in pre-market trading on October 20, 2026 at 8:59 a.m. CEST. The company had presented detailed Phase 2/3 results for investigational TAK-881 on October 14, 2026, according to Takeda.

TAK-881 cuts infusion burden

The IgGNITE trial met its primary endpoint in patients aged 16 years and older, showing pharmacokinetic comparability with HYQVIA. TAK-881 delivered the same immunoglobulin dose in 50.00 percent less volume while preserving dosing of up to once per month.

The operational difference was measurable. At one infusion site, median administration time fell from 132.00 minutes with HYQVIA to 75.80 minutes with TAK-881, a reduction of 56.20 minutes or 42.60 percent, according to Takeda. Treatment-emergent adverse events occurred in 56.10 percent of TAK-881 participants and 50.00 percent of HYQVIA participants.

Three dates frame the pipeline

On March 31, 2026, Takeda reported fiscal-year revenue of JPY 4.51 trillion, according to Reuters. On July 30, 2026, the company reported quarterly revenue of USD 7.66 billion and adjusted earnings per share of USD 0.23, according to Gekko. The October 14, 2026 TAK-881 update is the latest of these events.

When does Takeda report again?

Takeda's investor-relations page schedules the fiscal 2026 second-quarter earnings announcement for October 29, 2026, with an investor webcast later that day in Japan. That date gives the market a near-term test of the company's pipeline progress and financial execution.

What does the trial change?

The clinical data strengthen the practical case for TAK-881 by combining a 50.00 percent volume reduction with shorter administration at one infusion site. Regulatory applications in the United States, European Union and Japan are expected during fiscal year 2026, but the candidate remains investigational.

Stock price before the results date

The euro quotation places Takeda stock at EUR 17.75 in pre-market trading on October 20, 2026. The next scheduled company event is the fiscal 2026 second-quarter release on October 29, 2026.

The further course of trading is shown by the continuously updated real-time quote of Takeda stock.